INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 414m ago
HOUSE PTR14m ago
SEC 13F14m ago
ROBINHOOD CHAIN13m ago
Public company

MNPRMonopar Therapeutics

CIK 0001645469

EDGAR filingsOpen in network
Disclosed transactions18
Buys / sells0 / 8
Max Insider Score25
Connections3with evidence

MNPR · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
25
TR
Tsuchimoto Kim RDirector
MNPRMonopar Therapeutics
Open-market sale · 10b5-1 plan
SELL$84K
1,199 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Insider ofevidence
    Anderson RaymondDirector · Nov 4, 2026
  • ← Insider ofevidence
    Tsuchimoto Kim RDirector · Nov 4, 2026
10
AR
Anderson RaymondDirector
MNPRMonopar Therapeutics
Open-market sale · 10b5-1 plan
SELL
$14K
200 sh
Nov 2, 2026
Nov 4, 2026
traded Nov 2, 2026
+2d
SEC FORM 4

Evidence

21
AR
Anderson RaymondDirector
MNPRMonopar Therapeutics
Open-market sale · 10b5-1 plan
SELL$105K
1,502 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

0
AR
Anderson RaymondDirector
MNPRMonopar Therapeutics
Option exercise · 10b5-1 plan
M—
1,402 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

0
TR
Tsuchimoto Kim RDirector
MNPRMonopar Therapeutics
Option exercise · 10b5-1 plan
M$36K
1,199 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

7
TR
Tsuchimoto Kim RDirector
MNPRMonopar Therapeutics
Option exercise · 10b5-1 plan
M—
1,199 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

3
TR
Tsuchimoto Kim RDirector
MNPRMonopar Therapeutics
Option exercise · 10b5-1 plan
M—
856 sh
Nov 4, 2026Nov 4, 2026
traded Nov 4, 2026
+0dSEC FORM 4

Evidence

7
TR
Tsuchimoto Kim RDirector
MNPRMonopar Therapeutics
Option exercise · 10b5-1 plan
M—
2,035 sh
Nov 4, 2026Nov 4, 2026
traded Nov 4, 2026
+0dSEC FORM 4

Evidence

7
AR
Anderson RaymondDirector
MNPRMonopar Therapeutics
Option exercise · 10b5-1 plan
M$42K
1,402 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

10
AR
Anderson RaymondDirector
MNPRMonopar Therapeutics
Option exercise · 10b5-1 plan
M$52K
1,740 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

17
AR
Anderson RaymondDirector
MNPRMonopar Therapeutics
Open-market sale · 10b5-1 plan
SELL$56K
840 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

14
AR
Anderson RaymondDirector
MNPRMonopar Therapeutics
Open-market sale · 10b5-1 plan
SELL$40K
600 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

0
TR
Tsuchimoto Kim RDirector
MNPRMonopar Therapeutics
Option exercise · 10b5-1 plan
M$26K
856 sh
Nov 4, 2026Nov 4, 2026
traded Nov 4, 2026
+0dSEC FORM 4

Evidence

7
TR
Tsuchimoto Kim RDirector
MNPRMonopar Therapeutics
Option exercise · 10b5-1 plan
M$28K
2,035 sh
Nov 4, 2026Nov 4, 2026
traded Nov 4, 2026
+0dSEC FORM 4

Evidence

17
TR
Tsuchimoto Kim RDirector
MNPRMonopar Therapeutics
Open-market sale · 10b5-1 plan
SELL$92K
1,295 sh
Nov 4, 2026Nov 4, 2026
traded Nov 4, 2026
+0dSEC FORM 4

Evidence

21
TR
Tsuchimoto Kim RDirector
MNPRMonopar Therapeutics
Open-market sale · 10b5-1 plan
SELL$71K
996 sh
Nov 4, 2026Nov 4, 2026
traded Nov 4, 2026
+0dSEC FORM 4

Evidence

18
TR
Tsuchimoto Kim RDirector
MNPRMonopar Therapeutics
Open-market sale · 10b5-1 plan
SELL$43K
600 sh
Nov 4, 2026Nov 4, 2026
traded Nov 4, 2026
+0dSEC FORM 4

Evidence

0
AR
Anderson RaymondDirector
MNPRMonopar Therapeutics
Option exercise · 10b5-1 plan
M—
1,740 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence